CN102838649A - Preparation method of abiraterone acetate - Google Patents
Preparation method of abiraterone acetate Download PDFInfo
- Publication number
- CN102838649A CN102838649A CN 201210308040 CN201210308040A CN102838649A CN 102838649 A CN102838649 A CN 102838649A CN 201210308040 CN201210308040 CN 201210308040 CN 201210308040 A CN201210308040 A CN 201210308040A CN 102838649 A CN102838649 A CN 102838649A
- Authority
- CN
- China
- Prior art keywords
- preparation
- acetic acid
- compound
- abiraterone
- reaction
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Steroid Compounds (AREA)
Abstract
The invention belongs to the filed of medical technology, and particularly discloses a preparation method of abiraterone acetate, which comprises the following steps that compound I is acetylated to obtain compound II in an organic solvent, and compound II is coupled with halogenated pyridine to obtain the target product. The invention provides a preparation method of abiraterone acetate which can reduce the cost.
Description
Technical field
The invention belongs to medical technical field, be specifically related to a kind of preparation method of acetic acid Abiraterone.
Background technology
The acetic acid Abiraterone; Chemistry (3 β)-17-(3-pyridinyl) by name-Androsta-5; 16 – dien-3-ol acetate (ester) can treat late period the intractable prostate cancer of castrating that (transfevent) accepted the docetaxel treatment with retrocortine (steroidal compounds) coupling.
The male hormones Testosterone of patients with prostate cancer can stimulate tumor of prostate to increase, and medicine or operation can reduce Testosterone and produce or block the Testosterone influence.Even but prostate cancer also can continue development when the Testosterone level is very low under some situation, be the intractable prostate cancer of castrating like this.Acetic acid Abiraterone target is the protein of Cytochrome P450 17A1 (CYP17A1) by name, and this protein plays an important role for the generation of Testosterone.The acetic acid Abiraterone can reduce the generation of Testosterone and then prevent the cancer cells continued growth.The acetic acid Abiraterone can prolong advanced prostate cancer patient's life.
Summary of the invention
The method of bibliographical information is mainly at present:
The reagent cost that this method is used is high.Cause the finished product cost too high.
Technical problem to be solved by this invention has been to provide a kind of preparation method of new acetic acid Abiraterone, and productive rate and quality that it can obvious improved acetic acid Abiraterone reduce cost.
The preparation method of acetic acid Abiraterone of the present invention, it comprises following step:
1. in the organic solvent, the compound I acetylization reaction obtains intermediate II,
2. compound I I and haloperidid (compound III), coupling obtains target compound (TM).
Compound I I is (3 β)-17-iodo-androstane-5,16 – diene-3-alcohol acetic ester,
Compound III is 3-pyridine bromide or 3-iodo pyridine,
Target compound TM is the acetic acid Abiraterone.
1. step can adopt method and the condition of the conventional acetylization reaction in this area to carry out preferred following condition: step temperature of reaction 1. is preferable to be-15～150 ℃, and better is 50～80 ℃; Reaction times preferable with detection reaction fully till, be generally 2～22 h, that better is 5～7 h.Described organic solvent is the solvent of the conventional ability dissolved compound I that uses in this area; That preferable is THF, methylene dichloride, toluene, chloroform, tetracol phenixin, acetonitrile, N; In the dinethylformamide one or more, preferred THF, methylene dichloride; The consumption of solvent is 1～12 times of compound I, and better is 8～10 times (the ratio here is the volume mass ratio).Used acid binding agent is triethylamine, sodium hydrogencarbonate, saleratus, yellow soda ash, salt of wormwood.
2. step is alkylated reaction, and preferred following condition: compound I I carries out linked reaction with haloperidid under the situation that copper powder exists, and what the temperature of reaction was preferable is 20～250 ℃, and better is 180～220 ℃; The time of reaction is preferable be (with detection reaction complete till), is generally 2～24h, preferred 2～5h.
But each the optimum condition arbitrary combination among the preparation method of the present invention promptly gets each preferred embodiment of the present invention.
Reagent that the present invention is used and raw material are all commercially available to be got.
Positive progressive effect of the present invention has been to provide a kind of preparation method of new acetic acid Abiraterone, and it can obviously shorten the reactions step of acetic acid synthesized Abiraterone, improved acetic acid Abiraterone yield of product.
4. embodiment
Further specify the present invention with embodiment below, but the present invention is not limited.
Embodiment 1: the preparation of (3 β)-17-iodo-androstane-5,16 – diene-3-alcohol acetic ester (compound I I).
I II
In the 250ml there-necked flask, add 39.8 g (0.1mmol) compound I, 300 ml acetonitriles, 20 gram triethylamines, under normal temperature, in reaction system, drip 9.4 g (0.12mmol) Acetyl Chloride 98Min..Drip and finish, be warming up to 70 ℃ of reaction 4h, the TLC point sample detects, and shows that reaction finishes; Be cooled to room temperature, solvent is removed in distillation, obtains residue; Add 50ml water, ethyl acetate extraction (20ml * 3), anhydrous sodium sulfate drying, elimination siccative; The filtrate decompression distillation obtains white solid 38.7 g, yield: 97.9%.
MS(+1):441。
1HNMR：δ(ppm，CDCl
3)， 6.41-6.42(t，1H)，5.37-5.39 (t，H)，3.41-3.43 (q，2H)，2.87-2.89（m，1H），2.21-2.23(d，1H)，2.124-2.13 (d，1H)，2.01（s,3H），1.96-1.97 (dd，1H)，1.79.-1.80 (dd，1H)，1.52-1.54(m，3H)，1.48(m，1H)，1.44-1.45(m，2H)，1.38(dd，1H)，1.26-1.28(m，3H)，1.25（s，3H），1.24（s，3H）。
Embodiment 2: the preparation of acetic acid Abiraterone (compound TM)
In the 250ml there-necked flask that has reflux condensation mode, add 22.0 gram (3 β)-17-iodo-androstane-5,16 – diene-3-alcohol acetic esters (compound I I, 0.05mol), 15.3g 3-iodo pyridine (compound III, 0.075 mol).Stir, add copper powder 15.8g (0.25mol), be rapidly heated to 210 ℃, reaction 4h, the TLC detection reaction finishes; Cooling adds ETHYLE ACETATE, each 100 ml, wash-out 3 times; Merge organic phase, the water washing of 50mL saturated common salt once separates organic phase, anhydrous sodium sulfate drying 3h; The elimination siccative,, organic phase concentrates, and obtains the off-white color solid.(2:1,300mL) recrystallization once obtains white solid vacuum-drying to the off-white color solid that is obtained, and obtains 11.7g with ETHYLE ACETATE-sherwood oil.With ethyl alcohol recrystallization (120mL), the white solid vacuum-drying that is obtained obtains 8.32g with the 11.7g white solid that is obtained, total recovery 42.6%.
MS（+1）：392。
1HNMR：δ(ppm，CDCl
3)， 8.63(s,1H),8.47-8.48(d,1H),7.78-7.79(d,1H) ,7.33-7.34(dd,1H),6.42-6.43(t，1H)，5.37-5.38 (t，H)，3.42-3.43 (q，2H)，2.88-2.91（m，1H），2.20-2.22(d，1H)，2.12-2.14 (d，1H)，2.02（s,3H），1.97-1.98 (dd，1H)，1.79.-1.80 (dd，1H)，1.53-1.55(m，3H)，1.46-1.48(m，1H)，1.44-1.45(m，2H)，1.38-1.39(dd，1H)，1.27-1.29(m，3H)，1.26（s，3H），1.25（s，3H）。
Embodiment 3: (the preparation of (3 β)-17-iodo-androstane-5,16 – diene-3-alcohol acetic ester (compound I I).
I II
In the 250ml there-necked flask, add 39.8 g (0.1mmol) compound I, 300 ml methylene dichloride, 18g sodium hydrogencarbonate gram, under normal temperature, in reaction system, drip 9.4 g (0.12mmol) Acetyl Chloride 98Min..Drip and finish, be warming up to 75 ℃ of reaction 4h, the TLC point sample detects, and shows that reaction finishes; Be cooled to room temperature, the elimination inorganic salt, solvent is removed in the organic solvent distillation; Obtain residue, add 50ml water, ethyl acetate extraction (20ml * 3), anhydrous sodium sulfate drying; The elimination siccative, the filtrate decompression distillation obtains white solid 39.2 g, yield: 88.9%.
Nuclear magnetic data is with instance 1.
Claims (9)
1. the preparation method of an acetic acid Abiraterone, its preparation method comprises following step:
I II III TM
1. 17-iodo-Abiraterone-5,16-diene-3 β-alcohol (compound I) acetylize obtains compound I I;
2. compound I I and haloperidid (compound III) carry out coupling and obtain the acetic acid Abiraterone.
2. the preparation method of acetic acid Abiraterone as claimed in claim 1 is characterized in that: step 1., step temperature of reaction 2. is-50～220 ℃.
3. the preparation method of acetic acid Abiraterone as claimed in claim 1; It is characterized in that: step 1., in organic solvent be THF, methylene dichloride, toluene, N, one or more in dinethylformamide, acetone, chloroform, acetonitrile, tetracol phenixin, the acetonitrile.
4. the preparation method of acetic acid Abiraterone as claimed in claim 1 is characterized in that: the 1. middle acetylation reagent of step is aceticanhydride or Acetyl Chloride 98Min., and the consumption of compound I is that the mol ratio of acetylation reagent consumption is 1:1.2.
5. the preparation method of acetic acid Abiraterone as claimed in claim 1 is characterized in that: the method for step acetylization reaction 1. is under the effect of acid binding agent, and compound I and acetylation reagent carry out esterification.
6. the preparation method of acetic acid Abiraterone as claimed in claim 1 is characterized in that: the method for step reaction 2. is under the effect of copper powder, and compound I I and haloperidid (compound III) carry out the Ullmann linked reaction.
7. like the preparation method of claim 1,6 described acetic acid Abiraterones, it is characterized in that: step alkylated reaction 2., the consumption of compound III are that the mol ratio of haloperidid consumption is 1:2.2-15.
8. like the preparation method of claim 1,6,7 described acetic acid Abiraterones, it is characterized in that: used haloperidid is the 3-bromopyridine, the 3-iodine pyridine.
9. like the preparation method of claim 1,6,7,8 described acetic acid Abiraterones, it is characterized in that: the used compound III and the molar ratio of copper powder are: 1:5.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210308040 CN102838649A (en) | 2012-08-28 | 2012-08-28 | Preparation method of abiraterone acetate |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 201210308040 CN102838649A (en) | 2012-08-28 | 2012-08-28 | Preparation method of abiraterone acetate |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN102838649A true CN102838649A (en) | 2012-12-26 |
Family
ID=47366401
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 201210308040 Pending CN102838649A (en) | 2012-08-28 | 2012-08-28 | Preparation method of abiraterone acetate |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN102838649A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111253461A (en) * | 2020-01-15 | 2020-06-09 | 江西青峰药业有限公司 | Synthesis method of 7-oxoacetic acid abiraterone |
| CN116970020A (en) * | 2023-09-25 | 2023-10-31 | 天津凯莱英制药有限公司 | Abiraterone compound preparation method |
-
2012
- 2012-08-28 CN CN 201210308040 patent/CN102838649A/en active Pending
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111253461A (en) * | 2020-01-15 | 2020-06-09 | 江西青峰药业有限公司 | Synthesis method of 7-oxoacetic acid abiraterone |
| CN111253461B (en) * | 2020-01-15 | 2022-07-01 | 江西山香药业有限公司 | Synthesis method of 7-oxoacetic acid abiraterone |
| CN116970020A (en) * | 2023-09-25 | 2023-10-31 | 天津凯莱英制药有限公司 | Abiraterone compound preparation method |
| CN116970020B (en) * | 2023-09-25 | 2024-01-26 | 天津凯莱英制药有限公司 | Abiraterone compound preparation method |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102627681A (en) | Preparation method of abiraterone acetate | |
| CN105218610B (en) | Method for synthesizing cholesterol by using stigmasterol degradation products as raw materials | |
| CN105859728A (en) | Preparation method for ibrutinib | |
| CN103288725A (en) | Method for synthesising milrinone | |
| CN106349245A (en) | Sitagliptin phosphate impurities, method for preparing same and application of sitagliptin phosphate impurities | |
| CN106188116A (en) | A kind of method of synthesizing pyrazole 4 boric acid pinacol ester | |
| CN103664922A (en) | Novel crystal-form azilsartan and preparation method for same | |
| CN105566215A (en) | Preparation method of Stivarga | |
| CN103172690A (en) | Methods for preparing abiraterone acetate and intermediate thereof | |
| CN103833820A (en) | Synthetic method of 3- succinic acid-30-stearyl alcohol glycyrrhetinate | |
| CN110041214A (en) | A kind of Melphalan intermediate and preparation method thereof | |
| CN102838649A (en) | Preparation method of abiraterone acetate | |
| CN106699520A (en) | Method for synthesizing 3,3',5,5'-tetramethoxyl-4,4'-biphenol | |
| CN110790809B (en) | Preparation method of abiraterone acetate | |
| CN105237437B (en) | Entacapone impurity compound and preparation method thereof | |
| CN105753733A (en) | AHU377 crystal form and preparation method and uses thereof | |
| CN113336764A (en) | Bipyridine ligand with axial chirality and synthetic method thereof | |
| CN104230743A (en) | Method for preparing 4-benzyl-1-phenethyl piperazine-2,6-diketone | |
| CN110734398B (en) | New preparation method of 2-chloronicotinic acid | |
| CN103896889B (en) | Lapatinib intermediate and its preparation method and application | |
| CN103382171A (en) | Preparing method of Fudosteine oxidation impurities | |
| CN103509079B (en) | Ursolic acid derivative and preparation method thereof | |
| CN104513196B (en) | The synthetic method of roflumilast | |
| CN108794449B (en) | Synthetic method of deuterated fumaric acid vorofacian metabolite | |
| CN102532245B (en) | Ursolic acid derivative and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20121226 |